Compare MBUU & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | ABUS |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.5M | 848.1M |
| IPO Year | 2014 | N/A |
| Metric | MBUU | ABUS |
|---|---|---|
| Price | $29.70 | $4.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $33.57 | $5.00 |
| AVG Volume (30 Days) | 270.9K | ★ 1.1M |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $830,714,000.00 | $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | $30.05 | ★ N/A |
| Revenue Growth | 11.54 | ★ 116.64 |
| 52 Week Low | $24.07 | $2.71 |
| 52 Week High | $44.62 | $5.10 |
| Indicator | MBUU | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 60.87 |
| Support Level | $28.70 | $4.43 |
| Resistance Level | $30.41 | $4.63 |
| Average True Range (ATR) | 1.30 | 0.19 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 84.75 | 89.66 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.